In medicine posting now acs and lupus 101
Reading File
Finding Sources
Finding Sources
Reading File
Finding Sources
Reading File
Reading File
Finding Sources
Finding Sources
Reading File
Finding Sources
Finding Sources
Reading File
Reading File
I now have excellent material from Goldman-Cecil Medicine for both topics. Let me compile a comprehensive 101 guide.
ACS + Lupus (SLE) - Medicine Posting 101
PART 1: ACUTE CORONARY SYNDROME (ACS)
What Is ACS?
ACS is the continuum of myocardial ischemia/infarction - it spans three entities:
| Entity | Troponin | ST Changes |
|---|---|---|
| Unstable Angina (UA) | Negative | No STE |
| NSTEMI | Positive | No STE |
| STEMI | Positive | STE >20 min |
UA and NSTEMI together = Non-ST Elevation ACS (NSTE-ACS)
Pathophysiology
The central event is atherosclerotic plaque rupture or erosion - the fibrous cap breaks down, exposing the lipid core, which triggers:
- Platelet adhesion and aggregation
- Thrombus formation
- Subtotal (NSTEMI/UA) or total (STEMI) coronary occlusion
Type 1 MI - plaque rupture/thrombosis (classic ACS)
Type 2 MI - supply-demand mismatch (e.g., anemia, tachycardia, hypotension, thyrotoxicosis) - treat the underlying cause
Epidemiology
- ~1.2 million hospitalizations/year in the US
- 2/3 are NSTE-ACS
-
50% are over 65 years old
- Nearly half are women
Clinical Features
- Chest pain - new, worsening, or at rest
- Radiation to arm, jaw, or back
- Diaphoresis, nausea, dyspnea
- Silent MI is common in diabetics and elderly (atypical presentations)
Risk Stratification (two major scores)
TIMI Score (for NSTE-ACS) - 1 point each:
- Age >65
- 3+ atherosclerosis risk factors
- Known CAD
- 2+ anginal episodes in prior 24 hrs
- Aspirin use in prior 7 days
- ST deviation ≥0.5 mm
- Elevated troponin/CK-MB
Score 0-2 = low risk | 3-4 = intermediate | 5-7 = high risk
GRACE Score - uses: age, Killip class, heart rate, systolic BP, ST deviation, cardiac arrest at presentation, creatinine, biomarkers (available at outcomes-umassmed.org/grace)
Bleeding risk - female sex, older age, renal insufficiency, low body weight, tachycardia, extreme BP, anemia, diabetes (CRUSADE score)
Treatment Goals
- Prevent recurrent ischemia (correct O2 supply/demand)
- Prevent thrombus propagation
- Stabilize vulnerable plaque
Antianginal agents:
- Nitrates (nitroglycerin) - reduce preload/afterload
- Beta-blockers - reduce HR and O2 demand
- Calcium channel blockers - vasodilation
Antithrombotic agents:
- Aspirin - first line (loading dose + maintenance)
- P2Y12 inhibitors - clopidogrel or ticagrelor (given with aspirin = DAPT)
- Anticoagulants - unfractionated heparin (UFH), LMWH (enoxaparin), fondaparinux
Statins - plaque stabilization, started early
Revascularization:
- STEMI: Primary PCI within 90 min (door-to-balloon) is the gold standard; thrombolytics if PCI unavailable
- High-risk NSTE-ACS: Early invasive strategy (coronary angiography + PCI/CABG)
- Low-risk NSTE-ACS: Conservative strategy (no routine angiography needed)
PART 2: SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
What Is SLE?
SLE is a chronic, systemic autoimmune disease characterized by loss of tolerance to self-antigens, particularly nuclear material (dsDNA, histones), leading to immune complex deposition and multi-organ inflammation.
- Predominantly affects women of childbearing age (F:M ratio ~9:1)
- More common and severe in Black, Hispanic, and Asian women
Clinical Manifestations (approximate frequency)
| System | Manifestation | Frequency |
|---|---|---|
| Skin | Malar rash, DLE, photosensitivity, alopecia, oral ulcers | 88% |
| Musculoskeletal | Arthritis/arthralgias | 76% |
| Neuropsychiatric | Seizures, psychosis, cognitive dysfunction | 66% |
| Serosal | Pleurisy, pericarditis | 63% |
| Hematologic | Anemia | 57% |
| Vascular | Raynaud phenomenon | 44% |
| Vascular | Vasculitis | 43% |
| Cardiac | Atherosclerosis | 37% |
| Renal | Nephritis | 31% |
| Hematologic | Thrombocytopenia | 30% |
| Cardiac | Valvular disease (Libman-Sacks endocarditis) | 18% |
Cardiac note: Libman-Sacks endocarditis = sterile vegetations on the atrial side of the mitral valve. Pericarditis is the most common cardiac manifestation - pain relieved by leaning forward.
Renal note: >50% of SLE patients develop lupus nephritis at some point. WHO/ISN classes III and IV carry the worst prognosis.
Diagnosis - 2019 EULAR/ACR Classification Criteria
Step 1: ANA titer ≥1:80 is the entry criterion - if absent, do NOT classify as SLE
Step 2: Score the following (count only the highest-weighted item per domain):
| Domain | Item | Points |
|---|---|---|
| Constitutional | Fever | 2 |
| Neuropsychiatric | Delirium | 2 |
| Psychosis | 3 | |
| Seizure | 5 | |
| Mucocutaneous | Alopecia / oral ulcers | 2 |
| Subacute cutaneous / discoid lupus | 4 | |
| Acute cutaneous lupus (malar rash) | 6 | |
| Musculoskeletal | Joint involvement | 6 |
| Serosal | Pleural/pericardial effusion | 5 |
| Acute pericarditis | 6 | |
| Hematologic | Leukopenia | 3 |
| Thrombocytopenia | 4 | |
| Autoimmune hemolysis | 4 | |
| Renal | Proteinuria >0.5g/24h | 4 |
| Biopsy: class II/V LN | 8 | |
| Biopsy: class III/IV LN | 10 | |
| Immunologic | Antiphospholipid antibodies | 2 |
| Low C3 OR C4 | 3 | |
| Low C3 AND C4 | 4 | |
| Anti-dsDNA antibody | 6 |
Score ≥10 points + ANA positive = SLE
Key Antibodies to Know
| Antibody | Specificity | Association |
|---|---|---|
| ANA | Sensitive (95%) but not specific | Screening test |
| Anti-dsDNA | Highly specific | Active disease, lupus nephritis (titers correlate with activity) |
| Anti-Sm | Highly specific | Diagnostic of SLE |
| Anti-Ro/SS-A | Moderate | Neonatal lupus, photosensitivity, chilblain LE |
| Anti-La/SS-B | - | Neonatal lupus |
| Antiphospholipid | - | Thrombosis, recurrent miscarriage (APS) |
Treatment
Principles: treat to target (no active disease), prevent organ damage, minimize drug toxicity
| Severity | Treatment |
|---|---|
| Mild-moderate (skin, joints) | Hydroxychloroquine (all SLE patients unless contraindicated) + NSAIDs/low-dose steroids |
| Moderate-severe flare | Corticosteroids (prednisone 0.5-1 mg/kg/day) |
| Severe / organ-threatening | Pulse methylprednisolone + immunosuppressives (mycophenolate mofetil, azathioprine, cyclophosphamide) |
| Lupus nephritis class III/IV | MMF or cyclophosphamide + steroids |
| Refractory | Belimumab (anti-BLyS), voclosporin, anifrolumab |
Hydroxychloroquine is the backbone of SLE therapy - reduces flares, prevents organ damage, reduces thrombosis risk, safe in pregnancy.
Monitoring SLE Activity
- Anti-dsDNA titers rise with disease flares
- Complement levels (C3, C4) fall during active disease (consumed in immune complex deposition)
- CBC, urinalysis, creatinine - check regularly for cytopenias and renal involvement
- SLEDAI or BILAG scores for disease activity assessment
High-Yield Points for Wards
- "ANA positive but low titer" in an otherwise healthy person - don't chase it without clinical context
- Drug-induced lupus - caused by hydralazine, procainamide, isoniazid, minocycline (anti-histone antibodies; resolves on stopping the drug)
- Neonatal lupus - anti-Ro/La crosses placenta; can cause complete heart block in the neonate
- Antiphospholipid syndrome (APS) - occurs in ~30% of SLE; recurrent thrombosis and miscarriage; treat with anticoagulation (warfarin, LMWH)
- SLE patients have markedly accelerated atherosclerosis - cardiovascular disease is a leading cause of death in long-term SLE
Sources: Goldman-Cecil Medicine, International Edition; Fitzpatrick's Dermatology
Create a side-by-side comparison table of STEMI vs NSTEMI vs unstable angina
Here's a comprehensive side-by-side comparison:
ACS Comparison: STEMI vs NSTEMI vs Unstable Angina
| Feature | STEMI | NSTEMI | Unstable Angina |
|---|---|---|---|
| Full Name | ST-Elevation Myocardial Infarction | Non-ST-Elevation Myocardial Infarction | Unstable Angina Pectoris |
| Coronary Occlusion | Total occlusion | Subtotal / partial occlusion | Subtotal / partial occlusion (or spasm) |
| Troponin | ✅ Elevated | ✅ Elevated | ❌ Normal |
| CK-MB | ✅ Elevated | ✅ Elevated | ❌ Normal |
| ECG - ST Segment | ST elevation ≥1mm (≥2mm in V1-V4), or new LBBB | ST depression or T-wave changes | ST depression, T-wave changes, or normal |
| ECG - Q Waves | Develop later (transmural) | Usually absent | Absent |
| Pathology | Transmural (full thickness) infarct | Subendocardial infarct | No infarction - ischemia only |
| Myocyte Necrosis | ✅ Yes (extensive) | ✅ Yes (limited) | ❌ No |
| Thrombus Type | Occlusive red thrombus | Non-occlusive white/mixed thrombus | Non-occlusive / platelet-rich thrombus |
| Chest Pain Character | Severe, crushing, prolonged (>20 min) | Severe, prolonged | New-onset, worsening, or rest pain |
| Pain at Rest | ✅ Yes | ✅ Yes | ✅ Yes (key feature) |
| Urgency | 🔴 Immediate emergency | 🟠 Urgent | 🟡 Urgent |
| Time to Treatment | Door-to-balloon ≤90 min | Hours (risk-stratify first) | Hours (risk-stratify first) |
| Reperfusion Strategy | Primary PCI (preferred) or thrombolytics if PCI unavailable | PCI only (NO thrombolytics) | PCI only if high-risk; conservative if low-risk |
| Thrombolytics | ✅ Yes (if PCI unavailable within 120 min) | ❌ Contraindicated | ❌ Contraindicated |
| Aspirin | ✅ Yes | ✅ Yes | ✅ Yes |
| P2Y12 Inhibitor | ✅ Yes (ticagrelor or clopidogrel) | ✅ Yes | ✅ Yes (if high-risk) |
| Anticoagulation | ✅ Yes (UFH, bivalirudin) | ✅ Yes (UFH, LMWH, fondaparinux) | ✅ Yes |
| Beta-blocker | ✅ Yes (oral, early) | ✅ Yes | ✅ Yes |
| Statin | ✅ Yes (high intensity) | ✅ Yes | ✅ Yes |
| Mortality (in-hospital) | ~5-6% (higher) | ~3-4% | ~1-2% |
| Long-term Prognosis | Worse short-term | Worse long-term (more diffuse CAD) | Better if revascularized |
| Complications | Cardiogenic shock, free wall rupture, VF, complete heart block | Less mechanical complications | Progression to MI if untreated |
| Key Biomarker Timing | Troponin rises 3-6h, peaks 24h | Troponin rises 3-6h | Troponin: serial negatives needed |
Quick Memory Anchors
| STEMI | NSTEMI | UA | |
|---|---|---|---|
| Trop | ⬆️ | ⬆️ | ➡️ |
| ST | ⬆️ | ⬇️ or flat | ⬇️ or flat or normal |
| Lyse it? | ✅ | ❌ | ❌ |
| Full thickness? | ✅ | ❌ | ❌ |
One-Line Summary Each
- STEMI - total occlusion + ST elevation + elevated troponin = transmural infarct. Lyse or stent immediately.
- NSTEMI - partial occlusion + elevated troponin, no ST elevation = subendocardial infarct. Risk-stratify, then PCI.
- Unstable Angina - same as NSTEMI clinically, but troponin stays normal - ischemia without necrosis. Anti-ischemic therapy + risk stratification.
Note: UA and NSTEMI are managed identically in the acute phase because you cannot distinguish them until serial troponins return. The distinction is made retrospectively.
Source: Goldman-Cecil Medicine, International Edition
This is a shared conversation. Sign in to Orris to start your own chat.